Scholarlink

<p>Plasma phosphorylated tau 217 (pTau217) is an excellent biomarker of Alzheimer’s disease (AD) pathology, but it remains uncertain whether pTau217 can predict amyloid-β (Aβ) and tau accumulation prior to Aβ positron emission tomography (PET) positivity. Here, we leverage data from a well-characterized prospective cohort of cognitively unimpaired older adults to examine mass spectrometry-based plasma %pTau217 (pTau217/non-phosphorylated-Tau217×100) relative to changes in Aβ/tau PET and cognition. A higher baseline %pTau217 was associated with faster Aβ and tau accumulation on PET, which then led to greater cognitive decline. Among individuals Aβ PET-negative at baseline, higher %pTau217 levels presaged increases in Aβ and tau PET signals. Together, our results suggest that very low %pTau217 in cognitively unimpaired older adults is associated with a minimal risk of AD pathology accumulation&#xa0;and cognitive decline.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Plasma phosphorylated tau 217 and longitudinal trajectories of Aβ, tau, and cognition in cognitively unimpaired older adults

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月14日

查看全文
  • Hyun-Sik Yang,
  • Juliana A. U. Anzai,
  • Wai-Ying Wendy Yau,
  • Brian C. Healy,
  • Andrea M. Román Viera,
  • Courtney Maa,
  • Dylan Kirn,
  • Michael J. Properzi,
  • Jean-Pierre Bellier,
  • Aaron P. Schultz,
  • Michelle E. Farrell,
  • Heidi I. L. Jacobs,
  • Rachel F. Buckley,
  • Kathryn V. Papp,
  • Gad A. Marshall,
  • Rebecca E. Amariglio,
  • Dorene M. Rentz,
  • Lei Liu,
  • Dennis J. Selkoe,
  • Philip B. Verghese,
  • Joel B. Braunstein,
  • Keith A. Johnson,
  • Reisa A. Sperling,
  • Jasmeer P. Chhatwal

摘要

Plasma phosphorylated tau 217 (pTau217) is an excellent biomarker of Alzheimer’s disease (AD) pathology, but it remains uncertain whether pTau217 can predict amyloid-β (Aβ) and tau accumulation prior to Aβ positron emission tomography (PET) positivity. Here, we leverage data from a well-characterized prospective cohort of cognitively unimpaired older adults to examine mass spectrometry-based plasma %pTau217 (pTau217/non-phosphorylated-Tau217×100) relative to changes in Aβ/tau PET and cognition. A higher baseline %pTau217 was associated with faster Aβ and tau accumulation on PET, which then led to greater cognitive decline. Among individuals Aβ PET-negative at baseline, higher %pTau217 levels presaged increases in Aβ and tau PET signals. Together, our results suggest that very low %pTau217 in cognitively unimpaired older adults is associated with a minimal risk of AD pathology accumulation and cognitive decline.